Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain
Abstract
:1. Introduction
2. Results
2.1. Case 1
2.2. Case 2
2.3. Case 3
2.4. Case 4
2.5. Case 5
3. Discussion
3.1. NPS and Psychopathological Consequences
3.2. NPS Users and Psychiatric Comorbidities
- Previous psychiatric history, personality characteristics, and traumatic load may represent a point of vulnerability that, when interacting with substances, may lead to a major problem, both in the area of mood and thinking;
- The short-term consumption of large quantities or potent substances may contribute to the onset of psychotic symptoms or mood-independent effects.
- Could there be a broader base of substance users, increasing the number of people at risk due to predisposing factors? [2]
- Is it possible that the pursuit of boundaries explored by “psychonauts” online could extend into real-life trends?
3.3. Study Limitations
4. Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Degenhardt, L.; Whiteford, H.A.; Ferrari, A.J.; Baxter, A.J.; Charlson, F.J.; Hall, W.D.; Freedman, G.; Burstein, R.; Johns, N.; Engell, R.E.; et al. Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet 2013, 382, 1564–1574. [Google Scholar] [CrossRef] [PubMed]
- Mueser, K.T.; Drake, R.E.; Wallach, M.A. Dual diagnosis: A review of etiological theories. Addict. Behav. 1998, 23, 717–734. [Google Scholar] [CrossRef]
- Martinotti, G.; Chiappini, S.; Mosca, A.; Miuli, A.; Santovito, M.C.; Pettorruso, M.; Skryabin, V.; Sensi, S.L.; Di Giannantonio, M. Atypical antipsychotic drugs in dual disorders: Current evidence for clinical practice. Curr. Pharm. Des. 2022, 28, 2241–2259. [Google Scholar] [CrossRef]
- Harris, P.; Nagy, S.; Vardaxis, N.J. Mosby’s Dictionary of Medicine, Nursing and Health Professions; Elsevier: Chatswood, NSW, Australia, 2014; ISBN 9780323639149. [Google Scholar]
- Schifano, F.; Leoni, M.; Martinotti, G.; Rawaf, S.; Rovetto, F. Importance of cyberspace for the assessment of the drug abuse market: Preliminary results from the Psychonaut 2002 project. Cyberpsychol. Behav. Impact Internet Multimed. Virtual Real. Behav. Soc. 2003, 6, 405–410. [Google Scholar] [CrossRef]
- Schifano, F.; Deluca, P.; Agosti, L.; Martinotti, G.; Corkey, J.M.; Alex, B.; Caterina, B.; Heikki, B.; Raffaella, B.; Anna, C.; et al. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 (‘Blue Mystic’). J. Psychopharmacol. 2005, 19, 675–679. [Google Scholar] [CrossRef]
- Di Giannantonio, M.; Negri, A.; Schiavone, S.; Vannini, C.; Pettorruso, M.; De-Giorgio, F.; Verrastro, V.; Trabace, L.; Corbo, M.; Gottrado, R.; et al. Prescription Drug Misuse in “Clubbers” and Disco Goers in Ibiza. Front. Psychiatr. 2020, 11, 592–594. [Google Scholar] [CrossRef]
- Santacroce, R.; Corazza, O.; Martinotti, G.; Bersani, F.S.; Valeriani, G.; Di Giannantonio, M. Psyclones: A roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum. Psychopharmacol. 2015, 30, 265–271. [Google Scholar] [CrossRef]
- Martinotti, G.; Lupi, M.; Carlucci, L.; Cinosi, E.; Santacroce, R.; Acciavatti, T.; Chillemi, E.; Bonifaci, L.; Janiri, L.; Di Giannantonio, M. Novel psychoactive substances: Use and knowledge among adolescents and young adults in urban and rural areas. Hum. Psychopharmacol. 2015, 30, 295–301. [Google Scholar] [CrossRef]
- Corazza, O.; Valeriani, G.; Bersani, F.S.; Corkey, J.M.; Martinotti, G.; Bersani, G.; Schifano, F. “Spice”, “kryptonite”, “black mamba”: An overview of brand names and marketing strategies of novel psychoactive substances on the web. J. Psychoact. Drugs 2014, 46, 287–294. [Google Scholar] [CrossRef]
- Schifano, F.; Orsolini, L.; Papanti, D.; Corkey, J.M. NPS: Medical Consequences Associated with Their Intake. Curr. Top. Behav. Neurosci. 2017, 32, 351–380. [Google Scholar] [CrossRef]
- Scherbaum, N.; Schifano, F.; Bonnet, U. New Psychoactive Substances (NPS)—A Challenge for the Addiction Treatment Services. Pharmacopsychiatry 2017, 50, 116–122. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Chiappini, S.; Corkey, J.M.; Scherbaum, N.; Guirguis, A. The e-psychonaut drugs’ psychopharmacology. Curr. Opin. Pharmacol. 2021, 57, 165–174. [Google Scholar] [CrossRef] [PubMed]
- Schifano, F.; Napoletanp, F.; Chiappini, S.; Guirguis, A.; Corkery, J.M.; Bonaccorso, S.; Ricciardi, A.; Scherbaum, N.; Vento, A. New/emerging psychoactive substances and associated psychopathological consequences. Psychol. Med. 2021, 51, 30–42. [Google Scholar] [CrossRef] [PubMed]
- Corkey, J.M.; Schifano, F.; Martinotti, G. How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances. Br. J. Clin. Pharmacol. 2020, 86, 482–498. [Google Scholar] [CrossRef]
- ONUDD. World Drug Report 2015. Available online: https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf (accessed on 2 February 2024).
- Simonato, P.; Corazza, O.; Santonastaso, P.; Corkery, J.M.; Deluca, P.; Davey, Z.; Blaszko, U.; Schifano, F. Novel psychoactive substances as a novel challenge for health professionals: Results from an Italian survey. Hum. Psychopharmacol. 2013, 28, 324–331. [Google Scholar] [CrossRef]
- UNODC. World Drug Report 2022. Available online: https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html (accessed on 2 February 2024).
- Salomone, A.; Palamar, J.J.; Gerace, E.; Di Corcia, D.; Vincenti, M. Hair Testing for Drugs of Abuse and New Psychoactive Substances in a High-Risk Population. J. Anal. Toxicol. 2017, 41, 376–381. [Google Scholar] [CrossRef]
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Osservatorio Europeo Delle Droghe e Delle Tossicodipendenze EMCDDA. Available online: https://european-union.europa.eu/institutions-law-budget/institutions-and-bodies/search-all-eu-institutions-and-bodies/european-monitoring-centre-drugs-and-drug-addiction-emcdda_it (accessed on 2 February 2024).
- Chiappini, S.; Claridge, H.; Corkery, J.M.; Goodair, C.; Loi, B.; Schifano, F. Methoxetamine-related deaths in the UK: An overview. Hum. Psychopharmacol. 2015, 30, 244–248. [Google Scholar] [CrossRef]
- Loi, B.; Corkery, J.M.; Claridge, H.; Goodair, C.; Chiappini, S.; Gimeno Clemente, C.; Schifano, F. Deaths of individuals aged 16-24 years in the UK after using mephedrone. Hum. Psychopharmacol. 2015, 30, 225–232. [Google Scholar] [CrossRef]
- Corkery, J.M.; Schifano, F.; Oyefeso, A.; Ghodse, A.H.; Tonia, T.; Naidoo, V.; Button, J. Overview of literature and information on “khat-related” mortality: A call for recognition of the issue and further research. Ann. Ist. Super. Sanita 2011, 47, 445–464. [Google Scholar] [CrossRef]
- Whiteford, H.A.; Degenhardt, L.; Rehm, J.; Baxter, A.J.; Ferrari, A.J.; Erskine, H.E.; Charlson, F.J.; Norman, R.E.; Flaxman, A.D.; Johns, N.; et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 2013, 382, 1575–1586. [Google Scholar] [CrossRef]
- Kelly, D.; Hughes, K.; Bellis, M.A. Work hard, party harder: Drug use and sexual behaviour in young British casual workers in Ibiza, Spain. Int. J. Environ. Res. Public Health 2014, 11, 10051–10061. [Google Scholar] [CrossRef] [PubMed]
- Bellis, M.A.; Hale, G.; Bennett, A.; Chaudry, M.; Kilfoyle, M. Ibiza uncovered: Changes in substance use and sexual behaviour amongst young people visiting an international night-life resort. Int. J. Drug Policy 2000, 11, 235–244. [Google Scholar] [CrossRef] [PubMed]
- Hughes, K.; Bellis, M.A.; Chaudry, M. Elevated substance use in casual labour at international nightlife resorts: A case control study. Int. J. Drug Policy 2004, 15, 211–213. [Google Scholar] [CrossRef]
- Bellis, M.A.; Hughes, K.; Calafat, A.; Juan, M.; Schnitzer, S. Relative contributions of holiday location and nationality to changes in recreational drug taking behaviour: A natural experiment in the Balearic Islands. Eur. Addict. Res. 2009, 15, 78–86. [Google Scholar] [CrossRef]
- Bellis, M.A.; Hughes, K.; Bennett, A.; Thomson, R. The role of an international nightlife resort in the proliferation of recreational drugs. Addiction 2003, 98, 1713–1721. [Google Scholar] [CrossRef]
- von Sydow, K.; Lieb, R.; Pfister, H.; Höfler, M.; Wittchen, H.U. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend. 2002, 68, 49–64. [Google Scholar] [CrossRef]
- Santacroce, R.; Ruiz Bennasar, C.; Sancho Jaraiz, J.R.; Fiori, F.; Sarchione, F.; Angelini, F.; Catalano, G.; Carenti, M.L.; Corkery, J.M.; Schifano, F.; et al. A matter of life and death: Substance-caused and substance-related fatalities in Ibiza in 2015. Hum. Psychopharmacol. 2017, 32, e2592. [Google Scholar] [CrossRef]
- Hungerbuehler, I.; Buecheli, A.; Schaub, M. Drug Checking: A prevention measure for a heterogeneous group with high consumption frequency and polydrug use—Evaluation of zurich’s drug checking services. Harm Reduct. J. 2011, 8, 16. [Google Scholar] [CrossRef]
- Bellis, M.A.; Hughes, K.; Lowey, H. Healthy nightclubs and recreational substance use. From a harm minimisation to a healthy settings approach. Addict. Behav. 2002, 27, 1025–1035. [Google Scholar] [CrossRef]
- Martinotti, G.; Cinosi, E.; Santacroce, R.; Papanti, D.; Pasquini, A.; Mancini, V.; Corbo, M.; Fiori, F.; Sarchione, F.; Marchetti, D.; et al. Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. Hum. Psychopharmacol. 2017, 32, e2586. [Google Scholar] [CrossRef]
- Martinotti, G.; Negri, A.; Schiavone, S.; Montemitro, C.; Vannini, C.; Baroni, G.; Pettorruso, M.; De Giorgio, F.; Giorgetti, R.; Verrastro, V.; et al. Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients. Front. Psychiatry 2020, 879, 879. [Google Scholar] [CrossRef] [PubMed]
- Altintas, M.; Inanc, L.; Oruc, G.A.; Arpacioglu, S.; Gulec, H. Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: A single-center cross-sectional analysis of concurrently hospitalized patients. Neuropsychiatr. Dis. Treat. 2016, 12, 1893–1900. [Google Scholar] [CrossRef] [PubMed]
- Martinotti, G.; Santacroce, R.; Pettorruso, M.; Montemitro, C.; Spano, M.C.; Lorusso, M.; di Giannantonio, M.; Lerner, A.G. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci. 2018, 8, 47. [Google Scholar] [CrossRef] [PubMed]
- Caton, C.L.; Drake, R.E.; Hasin, D.S.; Dominguez, B.; Shrout, P.E.; Samet, S.; Schanzer, B. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch. Gen. Psychiatry 2005, 62, 137–145. [Google Scholar] [CrossRef]
- von Weizsäcker, V. Gesammelte Schriften/4 Der Gestaltkreis. Theorie der Einheit von Wahrnehmen und Bewegen; Suhrkamp: Stuttgart, Germany, 1950; ISBN 10 3518577794. [Google Scholar]
- Di Petta, G. Il mondo Tossicomane. Fenomenologia e Psicopatologia; FrancoAngeli: Milano, Italy, 2004; Volume 19, ISBN 88-464-6039-1. [Google Scholar]
- Martinotti, G.; Di Nicola, M.; Quattrone, D.; Santacroce, R.; Schifano, F.; Murray, R.; Di Giannantonio, M. Novel psychoactive substances and induced phenomena in psychopathology: The lysergic psychoma. J. Psychopathol. 2015, 21, 400–405. [Google Scholar]
- Acciavatti, T.; Lupi, M.; Santacroce, R.; Aguglia, A.; Attademo, L.; Bandini, L.; Ciambrone, P.; Lisi, G.; Migliarese, G.; Pinna, F.; et al. Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. Hum. Psychopharmacol. 2017, 32, e2578. [Google Scholar] [CrossRef]
- Vik, P.W.; Cellucci, T.; Jarchow, A.; Hedt, J. Cognitive impairment in substance abuse. Psychiatr. Clin. N. A. 2004, 27, 102–113. [Google Scholar] [CrossRef]
- Starzer, M.S.K.; Nordentoft, M.; Hjorthøj, C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am. J. Psychiatry 2018, 175, 343–350. [Google Scholar] [CrossRef]
- Johnson, J.M.; Wu, C.Y.; Winder, G.S.; Casher, M.I.; Marshall, V.D.; Bostwick, J.R. The Effects of Cannabis on Inpatient Agitation, Aggression, and Length of Stay. J. Dual Diagn. 2016, 12, 244–251. [Google Scholar] [CrossRef]
- Fiorentini, A.; Sara Volonteri, L.; Dragogna, F.; Rovera, C.; Maffini, M.; Carlo Mauri, M.; Altamura, C.A. Substance-Induced Psychoses: A Critical Review of the Literature. Curr. Drug Abus. Rev. 2011, 4, 228–240. [Google Scholar] [CrossRef]
- Papanti, D.; Schifano, F.; Botteon, G.; Bertossi, F.; Mannix, J.; Vidoni, D.; Impagnatiello, M.; Pascolo-Fabrici, E.; Bonavigo, T. “Spiceophrenia”: A systematic overview of “Spice”-related psychopathological issues and a case report. Hum. Psychopharmacol. Clin. Exp. 2013, 28, 379–389. [Google Scholar] [CrossRef] [PubMed]
- Martinotti, G.; De Risio, L.; Vannini, C.; Schifano, F.; Pettorruso, M.; Di Giannantonio, M. Substance-related exogenous psychosis: A postmodern syndrome. CNS Spectr. 2021, 26, 84–91. [Google Scholar] [CrossRef] [PubMed]
- Ferri, P.; Silvestri, M.; Artoni, C.; Di Lorenzo, R. Workplace violence in different settings and among various health professionals in an Italian general hospital: A cross-sectional study. Psychol. Res. Behav. 2016, 9, 263–275. [Google Scholar] [CrossRef] [PubMed]
- Chiappini, S.; Vaccaro, G.; Mosca, A.; Miuli, A.; Stigliano, G.; Stefanelli, G.; Giovannetti, G.; Carullo, R.; d’Andrea, G.; Di Carlo, F.; et al. New trends of drug abuse in custodial settings: A systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances. Neurosci. Biobehav. Rev. 2024, 162, 10569. [Google Scholar] [CrossRef]
- Martinotti, G.; Lupi, M.; Carlucci, L.; Santacroce, R.; Cinosi, E.; Acciavatti, T.; Sarchione, F.; Verrastro, V.; Diotaiuti, P.; Petruccelli, I.; et al. Alcohol drinking patterns in young people: A survey-based study. J. Health Psycho. 2017, 22, 1889–1896. [Google Scholar] [CrossRef]
- Chiappini, S.; Mosca, A.; Miuli, A.; Santovito, M.C.; Orsolini, L.; Corkery, J.M.; Guirguis, A.; Pettorruso, M.; Martinotti, G.; Di Giannantonio, M.; et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. Medicina 2021, 57, 580. [Google Scholar] [CrossRef]
- Mosca, A.; Chiappini, S.; Miuli, A.; Mancusi, G.; Santovito, M.C.; Di Carlo, F.; Pettorruso, M.; Corkery, J.M.; Canessa, C.; Martinotti, G.; et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr. Neuropharmacol. 2023, 21, 2178–2194. [Google Scholar] [CrossRef]
- Nutt, D. New psychoactive substances: Pharmacology influencing UK practice, policy and the law. Br. J. Clin. Pharmacol. 2020, 86, 445–451. [Google Scholar] [CrossRef]
- Vicknasingam, B.; Narayanan, S.; Singh, D.; Corazza, O. Global strategy for New Psychoactive Substances: An update. Curr. Opin. Psychiatry 2020, 33, 295–300. Available online: https://pubmed.ncbi.nlm.nih.gov/32398543/ (accessed on 2 September 2024). [CrossRef]
Cases | Gender; Age | Substance | Medical/Psychiatric Comorbidity | Symptoms | Treatment | Discharge Diagnosis |
---|---|---|---|---|---|---|
Case 1 | Female, 27 yrs | Simultaneously poly-abuse (cocaine, ecstasy, and alcohol) | None | Psychotic episode with delusional ideations, conceptual disorganization; paranoia; psychomotor agitation, verbal and outwardly directed aggression, and emotional lability; spatio-temporal disorientation; insomnia, lack of energy; confusion; mannerisms; and switching between languages | Olanzapine, haloperidol, and lorazepam | Substance-induced psychotic episode in borderline personality disorder |
Case 2 | Female, NA yrs | Methaqualone | None | Neglected in clothing and personal hygiene; agitation and aggressive behavior; genealogical/grandeur delusion with perseveration and mystic delirium; verbose and echolalic; and excessive thoughts of guilt and shame | Intravenous dose of diazepam; intravenous administrations of midazolam; and haloperidol | Substance-induced manic episode with mixed psychotic features |
Case 3 | Male, 20 yrs | None, only daily use of cannabis with and without alcohol in the last two weeks. Occasional use of methamphetamine, lysergic acid diethylamide (LSD), and ketamine | Alcohol, cannabis, and methamphetamine use in addition to another unknown liquid psychoactive substance | Disorganization; amnesia; perceptual alterations, visual hallucinations, and pseudo-hallucinations; and paranoia | NA | Substance-induced psychotic episode |
Case 4 | Female, 43 yrs | Cocaine, amphetamines, alcohol, and a probably unknown substance that someone else would have put in her drink | None | Manic episode with aggressiveness and psychomotor excitement; pressing speech with the tendency to derail thinking and speaking in three languages. Euphoria; mannerisms disorientation. Amnesia and difficulties in keeping attention | Haloperidol and loxapine | Substance-induced manic episode |
Case 5 | Male, 27 yrs | Alcohol and cocaine use disorders, with a regular intake of topiramate and disulfiram | Paranoid ideation and delusional about poisoning; aggressiveness and suspiciousness, manic symptoms | Haloperidol and loxapine | Substance-induced psychotic episode |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Montemitro, C.; Mosca, A.; Chiappini, S.; Miuli, A.; Schifano, F.; Montano, M.J.G.; Villar, C.M.d.; Allegretti, R.; Marrangone, C.; Di Petta, G.; et al. Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. Pharmaceuticals 2024, 17, 1387. https://doi.org/10.3390/ph17101387
Montemitro C, Mosca A, Chiappini S, Miuli A, Schifano F, Montano MJG, Villar CMd, Allegretti R, Marrangone C, Di Petta G, et al. Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. Pharmaceuticals. 2024; 17(10):1387. https://doi.org/10.3390/ph17101387
Chicago/Turabian StyleMontemitro, Chiara, Alessio Mosca, Stefania Chiappini, Andrea Miuli, Fabrizio Schifano, Maria Josè Gordillo Montano, Cristina Merino del Villar, Rita Allegretti, Carlotta Marrangone, Gilberto Di Petta, and et al. 2024. "Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain" Pharmaceuticals 17, no. 10: 1387. https://doi.org/10.3390/ph17101387
APA StyleMontemitro, C., Mosca, A., Chiappini, S., Miuli, A., Schifano, F., Montano, M. J. G., Villar, C. M. d., Allegretti, R., Marrangone, C., Di Petta, G., De Berardis, D., Pettorruso, M., & Martinotti, G. (2024). Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. Pharmaceuticals, 17(10), 1387. https://doi.org/10.3390/ph17101387